ObsEva Announces Update on Board of Directors
19 mars 2024 02h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
28 févr. 2024 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Geneva Court Grants Temporary Moratorium to ObsEva
31 janv. 2024 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
30 nov. 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Recovers Full Worldwide Rights on Nolasiban
13 juil. 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
02 mai 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
24 févr. 2023 07h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
24 févr. 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
01 déc. 2022 16h01 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical...
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
26 oct. 2022 17h00 HE
|
ObsEva SA
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7...